Skip Navigation

Steven P. Treon, MD, PhD


Medical Oncology

Make an Appointment

Physician

  • Director, Bing Center for Waldenström's Macroglobulinemia
  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Waldenström’s Macroglobulinemia

Contact Information

  • Office Phone Number617-632-4218
  • Fax617-632-4862

Bio

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia Research and an attending physician for medical oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. After earning a doctorate in tumor immunology from Boston University (BU), Dr. Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr. Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr. Treon also served a clinical fellowship in hematology and oncology at Mass. General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997. Dr. Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies, including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia.

Board Certification:

  • Medical Oncology, 1997

Fellowship:

  • Massachusetts General Hospital, Hematology & Oncology

Residency:

  • Boston University Medical Center, Internal Medicine

Medical School:

  • Boston University School of Medicine

Research

Immunotherapy of Plasma Cell Dyscrasias

Our research has focused on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia (WM) and on developing therapeutics for this B cell malignancy, which affects 6,000 to 10,000 patients a year in the United States. As part of our efforts, we recently characterized a familial form of WM, describing its incidence and clinical, laboratory, and cytogenetic characteristics. Importantly, we also demonstrated differing patterns of gene losses among WM patients, including the genes BLIMP1, PAX5, and members of the unfolded protein response (UPR), including XBP1 and IRE1a. Our studies have also provided important insight into the pathogenesis of WM by demonstrating a role for the excess mast cells found in the bone marrow of patients with WM. We recently demonstrated that mast cells serve as potent inducers of growth and enhancers of tumor cell survival through a host of mediators including CD40 ligand, a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (B-LYS) protein, platelet-derived growth factor (PDGF alpha), and vascular endothelial growth factor (VEGF). At the same time, we showed that WM tumor cells induce expression of several of these ligands through soluble CD27. These discoveries have helped in the development of novel therapeutic strategies targeting mast cells and mast cell-tumor cell interactions in WM. In other studies, we have sought to advance the therapy for WM by conducting clinical trials utilizing monoclonal antibodies as single agents and in combination with nucleoside analogs, cytotoxic agents, and immunomodulating agents, as well as phosphodiesterase and proteasome inhibitors. As part of this work, our lab has defined the mechanisms of action and resistance for these agents, specifically the role of Fc gamma receptor polymorphisms in predicting clinical responses to the CD20-directed monoclonal antibody rituximab. This work has resulted in several novel agents for treating WM, and ongoing clinical trials are evaluating their efficacy and toxicity.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 548B
Boston, MA 02215
Get Directions

Top